open access

Vol 55, No 1 (2021)
Guidelines
Published online: 2021-01-28
Submitted: 2020-10-16
Accepted: 2020-12-15
Get Citation

Migraine treatment recommendations developed by an Expert Group of the Polish Headache Society, the Headache Section of the Polish Neurological Society, and the Polish Pain Society

Adam Stępień, Wojciech Kozubski, Jacek J. Rożniecki, Izabela Domitrz
DOI: 10.5603/PJNNS.a2021.0007
·
Pubmed: 33507529
·
Neurol Neurochir Pol 2021;55(1):33-51.

open access

Vol 55, No 1 (2021)
Guidelines
Published online: 2021-01-28
Submitted: 2020-10-16
Accepted: 2020-12-15

Abstract

Not available

Abstract

Not available
Get Citation

Keywords

recommendations, guidelines, migraine, headaches, PTBG/PHS

About this article
Title

Migraine treatment recommendations developed by an Expert Group of the Polish Headache Society, the Headache Section of the Polish Neurological Society, and the Polish Pain Society

Journal

Neurologia i Neurochirurgia Polska

Issue

Vol 55, No 1 (2021)

Article type

Guidelines

Pages

33-51

Published online

2021-01-28

DOI

10.5603/PJNNS.a2021.0007

Pubmed

33507529

Bibliographic record

Neurol Neurochir Pol 2021;55(1):33-51.

Keywords

recommendations
guidelines
migraine
headaches
PTBG/PHS

Authors

Adam Stępień
Wojciech Kozubski
Jacek J. Rożniecki
Izabela Domitrz

References (147)
  1. Evers S, Afra J, Frese A, et al. European Federation of Neurological Societies. EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force. Eur J Neurol. 2009; 16(9): 968–981.
  2. Orr SL, Friedman BW, Christie S, et al. Management of adults with Acute Migraine in Emergency Department: The American Society Evidence Assessment of Parental Pharmacotherapies. Headache. 2016; 56: 911–940.
  3. Domitrz I, Kozubski W. Rekomendacje diagnostyczno-terapeutyczne postępowania w migrenie. Pol. Przegląd Neurol. 2019; 15(supp.B): 1–20.
  4. Stępień A. Rożniecki, Domitrz I. Leczenie pierwotnych bólów głowy. Ból. 2011; 12(4): 7–14.
  5. Dodick DW Migraine Lancet. 2018; 391(10127): 1315–1330.
  6. Goadsby PJ, Holland PR. Migraine Therapy: Current Approaches and New Horizons. Neurotherapeutics. 2018; 15(2): 271–273.
  7. Worthington I, Pringsheim T, Gawel MJ, et al. Canadian Headache Society Acute Migraine Treatment Guideline Development Group. Canadian Headache Society Guideline: acute drug therapy for migraine headache. Can J Neurol Sci. 2013; 40(5 Suppl 3): S1–S80.
  8. Lipton RB, Bigal ME, Diamond M, et al. AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007; 68(5): 343–349.
  9. Społeczne znaczenie migreny z perspektywy zdrowia publicznego i systemu ochrony zdrowia. Nnational Institut of Public Health (pzh) Raport. : Warszawa.
  10. Prencipe M, Gasini AR, Ferretti C. Prevalence of headache in an elderly population: attack frequency, disability, and use of medication. J Neurol Neurosurg Psychiatry. 2001; 70: 377–381.
  11. Goldstein M, Chen TC. The Epidemiology of distabling headache. W: Critchley M, Advances in neurology. New York, Raven Press. 1982; 33: 377–390.
  12. Laurell K, Artto V, Bendtsen L, et al. Premonitory symptoms in migraine: A cross-sectional study in 2714 persons. Cephalalgia. 2016; 36(10): 951–959.
  13. Denuelle M, Fabre N, Payoux P, et al. Hypothalamic activation in spontaneous migraine attacks. Headache. 2007; 47(10): 1418–1426.
  14. May A, Bahra A, Büchel C, et al. Hypothalamic activation in cluster headache attacks. Lancet. 1998; 352(9124): 275–278.
  15. Kreczmański P, Wolak T, Lewandowska M, et al. Altered functional brain imaging in migraine patients: BOLD preliminary study in migraine with and without aura. Neurol Neurochir Pol. 2019; 53(4): 304–310.
  16. Chądzyński P, Kacprzak A, Domitrz W, et al. Migraine headache facilitators in a population of Polish women and their association with migraine occurrence - preliminary results. Neurol Neurochir Pol. 2019; 53(5): 377–383.
  17. World Health Organization. Global Health Estimates 2015: Disease Burden by Cause, Age, Sex, by Country and by Region, 2000–2015. Geneva, 2016. Available at: http://www.who.int/healthinfo/global_burden_disease/estimates/en/index2.html. Accessed October. ; 26: 2018.
  18. Linde M, Gustavsson A, Stovner LJ, et al. The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol. 2012; 19(5): 703–711.
  19. Stewart WF, Lipton PR, Celentano DD, et al. Prevalence of migraine headache in United States. Relation to age, icome, race and other sociodemographic factors. JAMA. 1992; 267: 64–9.
  20. Domitrz I, Lipa A, Rożniecki J, et al. Treatment and management of migraine in neurological ambulatory practice in Poland by indicating therapy with monoclonal anti-CGRP antibodies. Neurologia i Neurochirurgia Polska. 2020; 54(4): 337–343.
  21. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias, and facial pain. Cephalalgia. 1988; 8: 1–96.
  22. Headache Classification Committee of the International Headache Society, International Classification of Headache Disorders. Cephalalgia. 2004; 24(S1): 9–160.
  23. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013; 33(9): 629–808.
  24. Prusiński A. Migrena w praktyce lekarza rodzinnego Świat Medycyny. 2003; 3(44): 23–28.
  25. Linde M, Mellberg A, Dahlöf C. The natural course of migraine attacks. A prospective analysis of untreated attacks compared with attacks treated with a triptan. Cephalalgia. 2006; 26(6): 712–721.
  26. Silberstein SD. Migraine symptoms: results of a survey of self-reported migraineurs. Headache. 1995; 35(7): 387–396.
  27. Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache. 2015; 55(1): 3–20.
  28. Becker WJ. Acute Migraine Treatment in Adults. Headache. 2015; 55(6): 778–793.
  29. Diener HC, Bussone G, de Li, et al. Placebocontrolled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia. 2004; 24: 947–954.
  30. Nebe J, Heier M, Diener HC. Low-dose ibuprofen in self-medication of mild to moderate headache: a comparison with acetylsalicylic acid and placebo. Cephalalgia. 1995; 15(6): 531–535.
  31. Dahlo¨f C, Bjo¨rkman R. Diclofenac-K (50 and 100 mg) and placebo in the acute treatment of migraine. Cephalalgia. 1993; 13: 117–123.
  32. Diener HC, Bussone G, de Li, et al. Placebocontrolled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia. 2004; 24: 947–954.
  33. Ward N, Whitney C, Avery D, et al. The analgesic effects of caffeine in headache. Pain. 1991; 44(2): 151–155.
  34. Fiebich BL, Lieb K, Kammerer N, et al. Effects of caffeine and paracetamol alone or in combination with acetylsalicylic acid on prostaglandin E(2) synthesis in rat microglial cells. Neuropharmacology. 2000; 39(11): 2205–2213.
  35. Yűcel A, Őzyalein S. Talu GK, Yűcel EC, Erdine S. Intarvenous administration of caffeine sodium benzoate for postura punctate headache. Rg Anesth Pain Med. 1999; 2: 51–4.
  36. Dinner HC, Pfaffenrath V, Pageler L, et al. The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination fort the treatment of headache: a multicentre, randomized, double – blind, single – dose, placebo – controlled parallel group study. Cephalalgia. 2005; 25: 776–787.
  37. Goldstein J, Silberstein S, Saper J, et al. Acetaminophen, Aspirin, and Caffeine Versus Sumatriptan Succinate in the Early Treatment of Migraine: Results From the ASSET trial. Headache: The Journal of Head and Face Pain. 2005; 45(8): 973–982.
  38. Bigal ME, Bordini CA, Tepper SJ, et al. Intravenous dipyrone in the acute treatment of migraine without aura and migraine with aura: a randomized, double blind, placebo controlled study. Headache. 2002; 42(9): 862–871.
  39. W. Kozubski: Metamizole and hydrocortisone for the interruption of migraine attack – preliminary study. Headache Quarterly 3. ; 1992: 309.
  40. Stępień A, Kozubski W. Ocena skuteczności leczenia napadu migreny acetylosalicylanem lizyny w połączeniu z chlorowodorkiem metoklopramidu. Pol. Merk. Lek. 2004; XVII. ; 102: 615–619.
  41. Titus F, Escamilla C, Palmeira MG, et al. A Double-Blind Comparison of Lysine Acetylsalicylate plus Metoclopramide vs Ergotamine plus Caffeine in Migraine. Clinical Drug Investigation. 2001; 21(2): 87–94.
  42. Friedman BW, Corbo J, Lipton RB, et al. A trial of metoclopramide vs sumatriptan for the emergency department treatment of migraines. Neurology. 2005; 64(3): 463–468.
  43. Láinez MJA, Galván J, Heras J, et al. Crossover, double-blind clinical trial comparing almotriptan and ergotamine plus caffeine for acute migraine therapy. Eur J Neurol. 2007; 14(3): 269–275.
  44. Welch KM. Stroke and migraine—the spectrum of cause and effect. Funct Neurol. 2003; 18: 121–126.
  45. Ferrari M. Migraine. The Lancet. 1998; 351(9108): 1043–1051.
  46. Ferrari MD, Roon KI, Lipton RB, et al. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001; 358(9294): 1668–1675.
  47. Derry S, Moore R, McQuay H. Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. Cochrane Database of Systematic Reviews. 2010.
  48. Colman SS, Brod MI, Krishnamurthy A, et al. Treatment satisfaction, functional status, and health-related quality of life of migraine patients treated with almotriptan or sumatriptan. Clin Ther. 2001; 23(1): 127–145.
  49. Pascual J, Cabarrocas X. Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better. Headache. 2002; 42(1): 28–31.
  50. Klapper J, Lucas C, Røsjø Ø, et al. ZODIAC study group. Benefits of treating highly disabled migraine patients with zolmitriptan while pain is mild. Cephalalgia. 2004; 24(11): 918–924.
  51. Smith LA, Oldman AD, McQuay HJ, et al. Eletriptan for acute migraine. Cochrane Database Syst Rev. 2001(3): CD003224.
  52. Láinez M. Clinical benefits of early triptan therapy for migraine. Cephalalgia. 2004; 24 Suppl 2: 24–30.
  53. Olesen J, Diener HC, Schoenen J, et al. No effect of eletriptan administration during the aura phase of migraine. Eur J Neurol. 2004; 11(10): 671–677.
  54. Goadsby PJ, Zanchin G, Geraud G, et al. Early vs. non-early intervention in acute migraine-'Act when Mild (AwM)'. A double-blind, placebo-controlled trial of almotriptan. Cephalalgia. 2008; 28(4): 383–391.
  55. Katsarava Z, Fritsche G, Muessig M, et al. Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology. 2001; 57: 1694–1698.
  56. Ferrari M. How to assess and compare drugs in the management of migraine: success rates in terms of response and recurrence. Cephalalgia. 1999; 19 Suppl 23: 2–4; discussion 4.
  57. Ferrari MD, James MH, Bates D, et al. Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrences. Cephalalgia. 1994; 14(5): 330–338.
  58. Hall GC, Brown MM, Mo J, et al. Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. Neurology. 2004; 62(4): 563–568.
  59. Stark S, Spierings EL, McNeal S, et al. Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan. Headache. 2000; 40(7): 513–520.
  60. Ferrari MD, Roon KI, Lipton RB, et al. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001; 358: 1668–1675.
  61. Dodick DW, Martin V. Triptans and CNS side effects: pharmacokinetic and metabolic mechanism. Cephalalgia. 2004; 24: 417–24.
  62. Orlova Y, Rizzoli P, Loder E. Association of Coprescription of Triptan Antimigraine Drugs and Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor Antidepressants With Serotonin Syndrome. JAMA Neurol. 2018; 75(5): 566–572.
  63. Tfelt–Hansen P. A reviev of evidence-based medicine and meta-analytic reviews in migraine. Cephalalgia. 2006; 26: 1265–1274.
  64. Mathew N, Kailasam J, Meadors L, et al. Intravenous valproate sodium (depacon) aborts migraine rapidly: a premilinary report. Headache. 2000; 40: 720–723.
  65. Leniger T, Pageler L, Stude P. Diener H-Ch, Limmorth V. Comparison of intravenous valproate with intravenous lysine – acetylsalicylic acid in acute migraine attacks. Headache. 2005; 45: 42–46.
  66. Mathew NT, Kailasam J, Meadors L, et al. Intravenous valproate sodium (depacon) aborts migraine rapidly: a preliminary report. Headache. 2000; 40(9): 720–723.
  67. Edwards KR, Norton J, Behnke M. Comparison of intravenous valproate versus intramuscular dihydroergotamine and metoclopramide for acute treatment of migraine headache. Headache. 2001; 41(10): 976–980.
  68. Norton J. Use of intravenous valproate sodium in status migraine. Headache. 2000; 40(9): 755–757.
  69. Bigal ME, Bordini CA, Tepper SJ, et al. Intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura. A randomized, double-blind, placebo-controlled study. Cephalalgia. 2002; 22(5): 345–353.
  70. DA approves new treatment for patients with migraine [press release]. https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-patients-migraine (October 11, 201).
  71. Goadsby PJ. Primary headache disorders: Five new things. Neurol Clin Pract. 2019; 9(3): 233–240.
  72. Oswald JC, Schuster NM. Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice. J Pain Res. 2018; 11: 2221–2227.
  73. Edvinsson L, Haanes KA, Warfvinge K, et al. CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol. 2018; 14(6): 338–350.
  74. Kuca B, Silberstein SD, Wietecha L, et al. COL MIG-301 Study Group. Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study. Neurology. 2018; 91(24): e2222–e2232.
  75. Goadsby PJ, Wietecha LA, Dennehy EB, et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain. 2019; 142(7): 1894–1904.
  76. Croop, R, Goadsby, PJ, Lipton, RB, Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: A randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019; 394: 737–745.
  77. Lipton RB, Manack A, Ricci JA, et al. Prevalence and burden of chronic migraine in adolescents: results of the chronic daily headache in adolescents study (C-dAS). Headache. 2011; 51(5): 693–706.
  78. D'Amico D, Grazzi L, Usai S, et al. Disability and quality of life in headache: where we are now and where we are heading. Neurol Sci. 2013; 34 Suppl 1: S1–S5.
  79. Stokes M, Becker WJ, Lipton RB, et al. Cost of health care among patients with chronic and episodic migraine in Canada and the USA: results from the International Burden of Migraine Study (IBMS). Headache. 2011; 51(7): 1058–1077.
  80. Bigal ME, Lipton RB. What predicts the change from episodic to chronic migraine? Curr Opin Neurol. 2009; 22(3): 269–276.
  81. Couch JR. Amitryptyline in the prophylactic treatment of migraine and chronic daily headache. Headache. 2011; 51: 33–51.
  82. Diener HC, Matias-Guiu J, Hartung E, et al. Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses: a comparison with propranolol 160 mg daily. Cephalalgia. 2002; 22(3): 209–221.
  83. Freitag FG, Collins SD, Carlson HA, et al. Depakote ER Migraine Study Group. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology. 2002; 58(11): 1652–1659.
  84. Brandes JL, Saper JR, Diamond M, et al. MIGR-002 Study Group. Topiramate for migraine prevention: a randomized controlled trial. JAMA. 2004; 291(8): 965–973.
  85. Diener HC, Tfelt-Hansen P, Dahlöf C, et al. MIGR-003 Study Group. Topiramate in migraine prophylaxis--results from a placebo-controlled trial with propranolol as an active control. J Neurol. 2004; 251(8): 943–950.
  86. Siniatchkin M, Andrasik F, Kropp P, et al. Central mechanisms of controlled-release metoprolol in migraine: a double-blind, placebo-controlled study. Cephalalgia. 2007; 27(9): 1024–1032.
  87. Linde K, Rossnagel K. Propranolol for migraine prophylaxis. Cochrane Database Syst Rev. 2004(2): CD003225.
  88. Messerli FH, Bangalore S, Julius S. Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension. Circulation. 2008; 117(20): 2706–15; discussion 2715.
  89. Maggioni F, Ruffatti S, Dainese F, et al. Weight variations in the prophylactic therapy of primary headaches: 6-month follow-up. J Headache Pain. 2005; 6(4): 322–324.
  90. Product Information: HEMANGEOL(TM) Oral Solution, Propranolol HCl Oral Solution. Pierre Fabre Pharmaceuticals, Inc. (per FDA), Parsippany, NJ. ; 2014.
  91. Cupini LM, Troisi E, Placidi F, et al. Does the antimigraine action of flunarizine involve the dopaminergic system? A clinical-neuroendocrinological study. Cephalalgia. 1999; 19(1): 27–31.
  92. Krusz JC, Scott V. Topiramate in the treatment of chronic migraine and other headaches. Headache. 1999; 39: 363–369.
  93. Von Seggern RL, Mannix LK, Adelman JU. Efficacy of topiramate in migraine prophylaxis: a retrospective chart analysis. Headache. 2002; 42(8): 804–809.
  94. Akerman S, Goadsby PJ. Topiramate inhibits cortical spreading depression in rat and cat: a possible contribution to its preventive effect in migraine. Cephalalgia. 2004; 24: 783–784.
  95. Diener HC, Bussone G, Van Oene JC, et al. TOPMAT-MIG-201(TOP-CHROME) Study Group. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007; 27(7): 814–823.
  96. Taylor FR. Weight change associated with the use of migraine-preventive medications. Clin Ther. 2008; 30(6): 1069–1080.
  97. Pascual J, Rivas MT, Leira R. Testing the combination beta-blocker plus topiramate in refractory migraine. Acta Neurol Scand. 2007; 115(2): 81–83.
  98. Bhoi SK, Kalita J, Misra UK. Is 6 months of migraine prophylaxis adequate? Neurol Res. 2013; 35(10): 1009–1014.
  99. Brandes JL, Saper JR, Diamond M, et al. MIGR-002 Study Group. Topiramate for migraine prevention: a randomized controlled trial. JAMA. 2004; 291(8): 965–973.
  100. Silberstein SD, Neto W, Schmitt J, et al. for the MIGR-001 Study Group. Topiramate in migraine prevention: Results of a large controlled trial. Arch Neurol. 2004; 61: 490–495.
  101. Klapper J. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia. 1997; 17(2): 103–108.
  102. FDA Drug Safety Communication. Children born to mothers who took valproate products while pregnant may have impaired cognitive development. Available at: https://www.fda.gov/Drugs/DrugSafety/ucm261543.htm. Accessed October. ; 26: 2018.
  103. Product Information: Depakote Oral Tablets, Divalproex Sodium Oral Tablets. AbbVie Inc. (per FDA), North Chicago, IL. ; 2015.
  104. Dodick DW, Freitag F, Banks J, et al. CAPSS-277 Investigator Group. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clin Ther. 2009; 31(3): 542–559.
  105. Bet PM, Hugtenburg JG, Penninx BW, et al. Side effects of antidepressants during long-term use in a naturalistic setting. Eur Neuropsychopharmacol. 2013; 23(11): 1443–1451.
  106. Fanoe S, Kristensen D, Fink-Jensen A, et al. Risk of arrhythmia induced by psychotropic medications: a proposal for clinical management. Eur Heart J. 2014; 35(20): 1306–1315.
  107. Mathew NT, Bendtsen L. Prophylactic pharmacotheraphy of tension-type headache. W Olesen J, Tfelt-Hansen P. The Headache, 2 wydanie, Rozdz. 88, Philadelphia; Lippioncott, Williams & Wilkins. ; 2000: 667–673.
  108. Bryson H, Wilde M. Amitriptyline. Drugs & Aging. 1996; 8(6): 459–476.
  109. Becker WJ. Evidence based migraine prophylactic drug therapy. Can J Neurol Sci. 1999; 26 Suppl 3: S27–S32.
  110. Diener HC, Dodick DW, Aurora SK, et al. PREEMPT 2 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010; 30(7): 804–814.
  111. Negro A, Curto M, Lionetto L, et al. OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study. Springerplus. 2015; 4: 826.
  112. Cernuda-Morollón E, Ramón C, Larrosa D, et al. Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: What happens after one year? Cephalalgia. 2015; 35(10): 864–868.
  113. Rothrock JF, Andress-Rothrock D, Michael A. Can botox be stopped? Discontinuing onabotulinumtoxin a therapy following remission in infrequent episodic migraine. Headache. 2016; 56: 30.
  114. VanderPluym J, Evans RW, Starling AJ. Long-Term Use and Safety of Migraine Preventive Medications. Headache. 2016; 56(8): 1335–1343.
  115. Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016; 86(19): 1818–1826.
  116. Sun H, Dodick DW, Silberstein S, et al. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2016; 15(4): 382–390.
  117. Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the Preventive Treatment of Chronic Migraine. N Engl J Med. 2017; 377(22): 2113–2122.
  118. Skljarevski V, Oakes TM, Zhang Qi, et al. Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial. JAMA Neurol. 2018; 75(2): 187–193.
  119. Goldstein ED, Badi MK, Meschia JF. Treating chronic migraine in CADASIL with calcitonin gene-related peptide receptor antagonism. Neurol Clin Pract. 2019; 9(3): 277–278.
  120. AHS Position Steatment on Integrating New Migraine Treatments Into Clinical Practice. Headache. 2019; 59: 1–18.
  121. Sacco European Headache Federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019; 20(1): 6.
  122. Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache. 2015; 55(1): 3–20.
  123. Silberstein S, Merriam G. Sex hormones and headache 1999 (menstrual migraine). Neurology. 1999; 53(4 Suppl 1): S3–13.
  124. Mattsson P. Hormonal factors in migraine: a population based study of women aged 40-74 years. Headache. 2003; 43: 27.
  125. Angst J, Sellaro R, Merikangas KR, et al. The epidemiology of perimenstrual psychological symptoms. Acta Psychiatr Scand. 2001; 104(2): 110–116.
  126. Solbach P, Sargent J, Coyne L. Menstrual migraine headache; results of a controlled, experimental, outcome study of nondrug treatments. Headache. 1984; 24: 75–78.
  127. MacGregor EA, Chia H, Vohrah RC, et al. Migraine and menstruation: a pilot study. Cephalalgia. 1990; 10(6): 305–310.
  128. Couturier EGM, Bomhof MAM. Knuistingh Neven A, van Duijn NI. Menstrual migraine in a representative Dutch population sample: prevalence, disability and treatment. Cephalalgia. 2003; 23: 302–308.
  129. Granella F, Sances G, Pucci E, et al. Migraine with aura and reproductive life events: a case controlled study. Cephalalgia. 2000; 20(8): 701–707.
  130. Newman L, Mannix LK, Landy S, et al. Naratriptan as Short-Term Prophylaxis of Menstrually Associated Migraine: A Randomized, Double-Blind, Placebo-Controlled Study. Headache: The Journal of Head and Face Pain. 2001; 41(3): 248–256.
  131. Silberstein SD, Elkind AH, Schreiber C, et al. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology. 2004; 63(2): 261–269.
  132. Newman L, Mannix LK, Landy S, et al. Naratriptan as Short-Term Prophylaxis of Menstrually Associated Migraine: A Randomized, Double-Blind, Placebo-Controlled Study. Headache: The Journal of Head and Face Pain. 2001; 41(3): 248–256.
  133. Pradalier A, Vincent D, Beaulieu PH, et al. Launay J-M. Correlation between estradiol plasma level and therapeutic effect on menstrual migraine. In: Proceedings of the 10th Migraine Trust Symposium. London. ; 1994: 129–132.
  134. Ephross SA, Sinclair SM. Final results from the 16-year sumatriptan, naratriptan, and treximet pregnancy registry. Headache. 2014; 54(7): 1158–1172.
  135. Brainin M, Barnes M, Baron JC, et al. Guideline Standards Subcommittee of the EFNS Scientific Committee. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces--revised recommendations 2004. Eur J Neurol. 2004; 11(9): 577–581.
  136. Silberstein S, Young WB, Mendizabal JE, et al. Efficacy of intramuscular droperidol for migraine treatment: a dose-response study. Cephalalgia 2001b. ; 21: 271–2.
  137. Tanen DA, Miller S, French T, et al. Intravenous sodium valproate versus prochlorperazine for the emergency department treatment of acute migraine headaches: a prospective, randomized, double-blind trial. Ann Emerg Med. 2003; 41(6): 847–853.
  138. Kabbouche M, Vockell AL, LeCates S, et al. Tolerability and Effectiveness of Prochlorperazine for Intractable Migraine in Children. Pediatrics. 2001; 107(4): e62–e62.
  139. Maizels M. Health resource utilization of the emergency department headache “Repeater” Headache. 2002; 42: 747–753.
  140. Friedman BW, Corbo J, Lipton RB, et al. A trial of metoclopramide vs sumatriptan for the emergency department treatment of migraines. Neurology. 2005; 64(3): 463–468.
  141. Long L, Ernst E, Ernst E. Homeopathic prophylaxis of headaches and migraine? A systematic review. J Pain Symptom Manage. 1999; 18(5): 353–357.
  142. Ulusoy EK, Bolattürk ÖF. The effect of greater occipital nerve blockade on the quality of life, disability and comorbid depression, anxiety, and sleep disturbance in patients with chronic migraine. Neurol Sci. 2020; 41(7): 1829–1835.
  143. Ashkenazi A, Blumenfeld A, Napchan U, et al. Interventional Procedures Special Interest Section of the American. Peripheral nerve blocks and trigger point injections in headache management - a systematic review and suggestions for future research. Headache. 2010; 50(6): 943–952.
  144. Riederer F, Penning S, Schoenen J. Transcutaneous Supraorbital Nerve Stimulation (t-SNS) with the Cefaly Device for Migraine Prevention: A Review of the Available Data. Pain Ther. 2015 [Epub ahead of print].
  145. Starling AJ, Tepper SJ, Marmura MJ, et al. A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study). Cephalalgia. 2018; 38(6): 1038–1048.
  146. Chou DE, Gross GJ, Casadei CH, et al. External Trigeminal Nerve Stimulation for the Acute Treatment of Migraine: Open-Label Trial on Safety and Efficacy. Neuromodulation. 2017; 20(7): 678–683.
  147. Varkey E, Cider A, Carlsson J, et al. Exercise as migraine prophylaxis: a randomized study using relaxation and topiramate as controls. Cephalalgia. 2011; 31(14): 1428–1438.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl